Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 4Oligodendroglioma 2Glioblastoma 2Astrocytoma 2Diffuse Intrinsic Pontine Glioma 1

Interventions

Temozolomide 5Irinotecan 3Cyclophosphamide 3Topotecan 2palbociclib 1olutasidenib 1nimotuzumab 1dostarlimab 1dipinacoline glutamate 1dinutuximab 1cemiplimab 1abemaciclib 1TIC10 compound 1Re-Irradiation 1OKN 007 1Maintenance 1Injections 1Granulocyte-Macrophage Colony-Stimulating Factor 1Etoposide 1Drug Tolerance 1Congresses as Topic 1CLR1404 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Diffuse Intrinsic Pontine Glioma × OKN 007 × Clear all
NCT05518838 2024-11-08

Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

Oblato, Inc.

No longer available
CNS

Diffuse Intrinsic Pontine Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡